WO2003082203A3 - Elastin prevents occlusion of body vessels by vascular smooth muscle cells - Google Patents

Elastin prevents occlusion of body vessels by vascular smooth muscle cells Download PDF

Info

Publication number
WO2003082203A3
WO2003082203A3 PCT/US2003/009391 US0309391W WO03082203A3 WO 2003082203 A3 WO2003082203 A3 WO 2003082203A3 US 0309391 W US0309391 W US 0309391W WO 03082203 A3 WO03082203 A3 WO 03082203A3
Authority
WO
WIPO (PCT)
Prior art keywords
smooth muscle
elastin
muscle cells
vascular smooth
body vessels
Prior art date
Application number
PCT/US2003/009391
Other languages
French (fr)
Other versions
WO2003082203A2 (en
Inventor
Dean Y Li
Satyajit Karnik
Original Assignee
Univ Utah Res Found
Dean Y Li
Satyajit Karnik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Utah Res Found, Dean Y Li, Satyajit Karnik filed Critical Univ Utah Res Found
Priority to US10/509,472 priority Critical patent/US20060079439A1/en
Priority to EP03726130A priority patent/EP1578352A2/en
Priority to AU2003228382A priority patent/AU2003228382A1/en
Publication of WO2003082203A2 publication Critical patent/WO2003082203A2/en
Publication of WO2003082203A3 publication Critical patent/WO2003082203A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
    • A61L29/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/05—Hydrolases acting on acid anhydrides (3.6) acting on GTP; involved in cellular and subcellular movement (3.6.5)
    • C12Y306/05002—Small monomeric GTPase (3.6.5.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Surgery (AREA)
  • Wood Science & Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides methods and compositions for promoting elastin signaling in smooth muscle cells including vascular smooth muscle cell. The present invention further provides methods of identifying additional agents that promote elastin signaling.
PCT/US2003/009391 2002-03-27 2003-03-27 Elastin prevents occlusion of body vessels by vascular smooth muscle cells WO2003082203A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/509,472 US20060079439A1 (en) 2002-03-27 2003-03-27 Elastin prevents occlusion of body vessels by vascular smooth muscle cells
EP03726130A EP1578352A2 (en) 2002-03-27 2003-03-27 Elastin prevents occlusion of body vessels by vascular smooth muscle cells
AU2003228382A AU2003228382A1 (en) 2002-03-27 2003-03-27 Elastin prevents occlusion of body vessels by vascular smooth muscle cells

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36808402P 2002-03-27 2002-03-27
US60/368,084 2002-03-27

Publications (2)

Publication Number Publication Date
WO2003082203A2 WO2003082203A2 (en) 2003-10-09
WO2003082203A3 true WO2003082203A3 (en) 2006-08-17

Family

ID=28675442

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/009391 WO2003082203A2 (en) 2002-03-27 2003-03-27 Elastin prevents occlusion of body vessels by vascular smooth muscle cells

Country Status (4)

Country Link
US (1) US20060079439A1 (en)
EP (1) EP1578352A2 (en)
AU (1) AU2003228382A1 (en)
WO (1) WO2003082203A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8460367B2 (en) 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US7175658B1 (en) * 2000-07-20 2007-02-13 Multi-Gene Vascular Systems Ltd. Artificial vascular grafts, their construction and use
HUP0300810A2 (en) 2000-07-20 2003-08-28 M.G.V.S. Ltd. Artifical vascular grafts, and methods of producing and using same
US7723308B2 (en) 2005-04-15 2010-05-25 Human Matrix Sciences, Llc Plant-derived elastin binding protein ligands and methods of using the same
JP2008532942A (en) * 2005-02-25 2008-08-21 ユニバーシティ オブ ユタ リサーチ ファウンデーション Methods and compositions for promoting endothelial cell adhesion or migration
FR2976587B1 (en) 2011-06-20 2015-04-03 Basf Beauty Care Solutions F IN VITRO DOSING METHOD BY IMMUNOLOGICAL TECHNIQUE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910490A (en) * 1993-08-17 1999-06-08 Roc. S.A. Use of oligosaccharides in the prevention and treatment of the aging of tissues
WO2000050068A2 (en) * 1999-02-26 2000-08-31 University Of Utah Research Foundation Elastin-based compositions

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352887A (en) * 1979-10-29 1982-10-05 Albert Einstein College Of Medicine Of Yeshiva University Method and article for culturing differentiated cells
US4323358A (en) * 1981-04-30 1982-04-06 Vascor, Inc. Method for inhibiting mineralization of natural tissue during implantation
US4960423A (en) * 1982-11-17 1990-10-02 Smith Donald W Method of enhancing the attachment of endothelial cells on a matrix and vascular prosthesis with enhanced anti-thrombogenic characteristics
US5852009A (en) * 1984-03-19 1998-12-22 The Rockefeller University Compositions, including pharmaceutical compositions, for inhibiting the advanced glycosylation of proteins, and therapeutic methods based thereon
US4553974A (en) * 1984-08-14 1985-11-19 Mayo Foundation Treatment of collagenous tissue with glutaraldehyde and aminodiphosphonate calcification inhibitor
US5064430A (en) * 1985-10-31 1991-11-12 Uab Research Foundation Polynonapeptide bioelastomers having an increased elastic modulus
US4976734A (en) * 1985-10-31 1990-12-11 Uab Research Foundation Stimulation of chemotaxis by chemotactic peptides
US4733665C2 (en) * 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US5336256A (en) * 1986-04-17 1994-08-09 Uab Research Foundation Elastomeric polypeptides as vascular prosthetic materials
US4877599A (en) * 1986-11-10 1989-10-31 New England Deaconess Hospital Corporation Detection of vascular disease with labelled antibodies
US5856245A (en) * 1988-03-14 1999-01-05 Nextec Applications, Inc. Articles of barrier webs
US5874164A (en) * 1988-03-14 1999-02-23 Nextec Applications, Inc. Barrier webs having bioactive surfaces
US5972890A (en) * 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5726153A (en) * 1988-05-02 1998-03-10 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
US5749895A (en) * 1991-02-13 1998-05-12 Fusion Medical Technologies, Inc. Method for bonding or fusion of biological tissue and material
US5591224A (en) * 1992-03-19 1997-01-07 Medtronic, Inc. Bioelastomeric stent
ATE312198T1 (en) * 1993-04-05 2005-12-15 Univ Utah Res Found DIAGNOSIS AND TREATMENT OF SUPRAVALVULAR AORTIC STENOSIS
US5858662A (en) * 1993-04-05 1999-01-12 University Of Utah Research Foundation Diagnosis of Williams syndrome and Williams syndrome cognitive profile by analysis of the presence or absence of a LIM-kinase gene
US5595571A (en) * 1994-04-18 1997-01-21 Hancock Jaffe Laboratories Biological material pre-fixation treatment
US5716394A (en) * 1994-04-29 1998-02-10 W. L. Gore & Associates, Inc. Blood contact surfaces using extracellular matrix synthesized in vitro
CA2186374A1 (en) * 1994-04-29 1995-11-09 William Carl Bruchman Improved blood contact surfaces employing natural subendothelial matrix and method for making and using the same
US5989244A (en) * 1994-11-15 1999-11-23 Gregory; Kenton W. Method of use of a sheet of elastin or elastin-based material
US5891558A (en) * 1994-11-22 1999-04-06 Tissue Engineering, Inc. Biopolymer foams for use in tissue repair and reconstruction
ZA963151B (en) * 1995-04-19 1997-04-24 St Jude Medical Matrix substrate for a viable body tissue-derived prosthesis and method for making the same
US5925552A (en) * 1996-04-25 1999-07-20 Medtronic, Inc. Method for attachment of biomolecules to medical devices surfaces
US5945319A (en) * 1996-04-25 1999-08-31 Medtronic, Inc. Periodate oxidative method for attachment of biomolecules to medical device surfaces
US5891506A (en) * 1996-08-09 1999-04-06 Medtronic, Inc. Oxidative method for attachment of glycoproteins or glycopeptides to surfaces of medical devices
US5928916A (en) * 1996-04-25 1999-07-27 Medtronic, Inc. Ionic attachment of biomolecules with a guanidino moiety to medical device surfaces
US5728420A (en) * 1996-08-09 1998-03-17 Medtronic, Inc. Oxidative method for attachment of glycoproteins to surfaces of medical devices
US5791352A (en) * 1996-06-19 1998-08-11 Fusion Medical Technologies, Inc. Methods and compositions for inhibiting tissue adhesion

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5910490A (en) * 1993-08-17 1999-06-08 Roc. S.A. Use of oligosaccharides in the prevention and treatment of the aging of tissues
WO2000050068A2 (en) * 1999-02-26 2000-08-31 University Of Utah Research Foundation Elastin-based compositions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KARNIK S.K. ET AL.: "A critical role for elastin signaling in vascular morphogenesis and disease", DEVELOPMENT, vol. 130, January 2003 (2003-01-01), pages 411 - 423, XP002414910 *

Also Published As

Publication number Publication date
AU2003228382A1 (en) 2003-10-13
EP1578352A2 (en) 2005-09-28
WO2003082203A2 (en) 2003-10-09
US20060079439A1 (en) 2006-04-13
AU2003228382A8 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
PL1641914T3 (en) Postpartum cells derived from placental tissue, and methods of making and using the same
EP1769791A3 (en) Treatment of Alzheimer's disease with cell cycle inhibitors
EP1894564A3 (en) Use of an ibat inhibitor for the treatment of prophylaxis of constipation
EP1501426A4 (en) Systems, methods, and compositions for achieving closure of vascular puncture sites
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2006068729A3 (en) Methods and compositions for enhancing iron absorption
WO2004021968A3 (en) Solution for ungual application
HK1047404A1 (en) Vascular coating composition
MX295630B (en) Continuous multi-microencapsulation process for improving the stability and storage life of biologically active ingredients.
WO2006052451A3 (en) Implantable collagen compositions
EP1764370A3 (en) Methods of treatment of inflammatory diseases using specific binding agents of human angiopoietin - 2
ZA200409492B (en) Compositions and methods for the diagnosis and treatment of tumor.
AU2003226367A1 (en) Electropolishing and electroplating methods
AU2003273276A1 (en) Methods and compositions for the preservation of cells, tissues or organs in the vitreous state
WO2004019884A3 (en) Agents and methods for enhancing bone formation
EP2767291A3 (en) Treatment of glycogen storage disease type II
WO2004039248A3 (en) Repairing or replacing tissues or organs
WO2007081419A3 (en) Compositions and methods related to anti-fgf agents
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2003082203A3 (en) Elastin prevents occlusion of body vessels by vascular smooth muscle cells
WO2005009366A3 (en) Restoring vascular function
WO2005052140A3 (en) Multipotent postnatal stem cells from human periodontal ligament and uses thereof
WO2003102162A3 (en) Novel tolerogenic dendritic cells and therapeutic uses therefor
WO2004078927A3 (en) Progenitor cells and methods of using same
TW200501957A (en) Use of dipyridamole in combination with acetylsalicylic acid and an angiotensin Ⅱ antagonist for stroke prevention

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003726130

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006079439

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10509472

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003726130

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10509472

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP